FDA Approves Unknown Drug — ASTRAZENECA AB

# FDA Approves AstraZeneca Drug, Expanding Treatment Options in Key Therapeutic Area The U.S. Food and Drug Administration has approved AstraZeneca AB's new drug application (NDA209091) as of February 27, 2017, positioning the pharmaceutical company to capture market share in an increasingly competitive therapeutic segment. The approval strengthens AstraZeneca's product portfolio and is expected to drive incremental revenue growth while enhancing the company's competitive standing against rival treatments.